Skip to main content
Premium Trial:

Request an Annual Quote

Waters Shares Sink 11.7 Percent After Company Cuts Revenue Projections, Its Second Cut in Seven Months

NEW YORK, Oct. 14 (GenomeWeb News) - Shares of Waters' stock were down 11.67 percent, or $4.83, at $36.55 in mid-afternoon trading after the company this morning reported that "slower thanexpected" sales growth has forced it to lower its third-quarter sales and earnings-per-share expectations.


In its second-quarter conference call July 26, Waters said it anticipated sales to grow 8 percent in the third quarter year over year. The company now expects growth to be around 3 percent year over year.


This is the secomd time in seven months that Waters was forced to lower its projections. In March, the company said it would revise its projected first-quarter earnings from $.44 to between $.34 and $.37 per diluted share. At that time, the firm also cited "weaker thanexpected sales growth" as cause for decreasing its sales growth projections to 3 to 4 percent from 13 to 14 percent.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.